2023 Pediatric ICD-10-CM Codes

Effective October 1, 2022

The 2023 changes to ICD-10-CM become effective on October 1, 2022. Listed below are the new codes we believe are of most interest to pediatricians. Please see your 2023 ICD-10-CM code book for a complete list of changes and to verify all new and revised codes.

Chapter 1  Certain Infectious and Parasitic Diseases

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>B37.31</td>
<td>Acute candidiasis of vulva and vagina</td>
</tr>
<tr>
<td>B37.32</td>
<td>Chronic candidiasis of vulva and vagina</td>
</tr>
</tbody>
</table>

Chapter 3  Diseases of the Blood and Blood-Forming Organs and Certain Disorders Involving the Immune Mechanism

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D68.00</td>
<td>Von Willebrand disease, unspecified</td>
</tr>
<tr>
<td>D68.01</td>
<td>Von Willebrand disease, type 1</td>
</tr>
<tr>
<td>D68.02x</td>
<td>Von Willebrand disease, type 2</td>
</tr>
<tr>
<td>D68.020</td>
<td>Von Willebrand disease, type 2A</td>
</tr>
<tr>
<td>D68.021</td>
<td>Von Willebrand disease, type 2B</td>
</tr>
<tr>
<td>D68.022</td>
<td>Von Willebrand disease, type 2M</td>
</tr>
<tr>
<td>D68.023</td>
<td>Von Willebrand disease, type 2N</td>
</tr>
<tr>
<td>D68.029</td>
<td>Von Willebrand disease, type 2, unspecified</td>
</tr>
<tr>
<td>D68.03</td>
<td>Von Willebrand disease, type 3</td>
</tr>
<tr>
<td>D68.04</td>
<td>Acquired von Willebrand disease</td>
</tr>
<tr>
<td>D68.09</td>
<td>Other von Willebrand disease</td>
</tr>
</tbody>
</table>

Chapter 4  Endocrine, nutritional and metabolic diseases

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E34.30</td>
<td>Short stature due to endocrine disorder, unspecified</td>
</tr>
<tr>
<td>E34.31</td>
<td>Constitutional short stature</td>
</tr>
<tr>
<td>E87.2x</td>
<td>Acidosis</td>
</tr>
</tbody>
</table>
E87.20 Acidosis, unspecified
E87.21 Acute metabolic acidosis
E87.22 Chronic metabolic acidosis
E87.29 Other acidosis

**Chapter 5**  **Mental, Behavioral and Neurodevelopment Disorders**

**F06.7x** Mild neurocognitive disorder due to known physiological condition

**F06.70** Mild neurocognitive disorder due to known physiological condition without behavioral disturbance

**F06.71** Mild neurocognitive disorder due to known physiological condition with behavioral disturbance

**F10.90** Alcohol use, unspecified, uncomplicated
**F10.91** Alcohol use, unspecified, in remission

**F11.9x** Opioid use, unspecified

**F11.91** Opioid use, unspecified, in remission

**F12.91** Cannabis use, unspecified, in remission
**F13.91** Sedative, hypnotic or anxiolytic use, unspecified, in remission
**F14.91** Cocaine use, unspecified, in remission
**F15.91** Other stimulant use, unspecified, in remission
**F16.91** Hallucinogen use, unspecified, in remission
**F18.91** Inhalant use, unspecified, in remission
**F19.91** Other psychoactive substance use, unspecified, in remission

**F43.8x** Other reactions to severe stress

**F43.81** Prolonged grief disorder
**F43.89** Other reactions to severe stress

**F43.9** Reaction to severe stress, unspecified

**Chapter 6**  **Diseases of the Nervous System**

**G93.31** Postviral fatigue syndrome
**G93.32** Myalgic encephalomyelitis/chronic fatigue syndrome
**G93.39** Other post infection and related fatigue syndromes
Chapter 14  Diseases of the genitourinary system

N80.0x  Endometriosis of uterus

N80.00  Endometriosis of the uterus, unspecified
N80.01  Superficial endometriosis of the uterus
N80.02  Deep endometriosis of the uterus
N80.03  Adenomyosis of the uterus

N80.10x  Endometriosis of ovary, unspecified depth

N80.101  Endometriosis of right ovary, unspecified depth
N80.102  Endometriosis of left ovary, unspecified depth
N80.103  Endometriosis of bilateral ovaries, unspecified depth
N80.109  Endometriosis of ovary, unspecified side, unspecified depth

N80.11x  Superficial endometriosis of the ovary

N80.111  Superficial endometriosis of right ovary
N80.112  Superficial endometriosis of left ovary
N80.113  Superficial endometriosis of bilateral ovaries
N80.119  Superficial endometriosis of ovary, unspecified ovary

N80.12x  Deep endometriosis of ovary

N80.121  Deep endometriosis of right ovary
N80.122  Deep endometriosis of left ovary
N80.123  Deep endometriosis of bilateral ovaries
N80.129  Deep endometriosis of ovary, unspecified ovary

Chapter 18  Symptoms, Signs and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified

R79.1  Abnormal coagulation profile

Chapter 19  Injury, Poisoning and Certain Other Consequences of External Causes

T43.65x  Poisoning by adverse effect of and underdosing of methamphetamines

T43.651  Poisoning by methamphetamines accidental (unintentional)
T43.652  Poisoning by methamphetamines intentional self-harm
T43.653  Poisoning by methamphetamines, assault
T43.654  Poisoning by methamphetamines, undetermined
T43.655  Adverse effect of methamphetamines
T43.656  Underdosing of methamphetamines
Chapter 20  External Causes of Morbidity

V20.0x  Motorcycle driver injured in collision with pedestrian or animal in nontraffic accident

V20.1x  Motorcycle passenger injured in collision with pedestrian or animal in nontraffic accident

V20.2x  Unspecified motorcycle rider injured in collision with pedestrian or animal in nontraffic accident

V20.3x  Person boarding or alighting a motorcycle injured in collision with pedestrian or animal

V20.4x  Motorcycle driver injured in collision with pedestrian or animal in traffic accident

V20.5x  Motorcycle passenger injured in collision with pedestrian or animal in traffic accident

V20.9x  Unspecified motorcycle rider injured in collision with pedestrian or animal in traffic accident

V21.0x  Motorcycle driver injured in collision with pedal cycle in nontraffic accident

V21.1x  Motorcycle passenger injured in collision with pedal cycle in nontraffic accident

V21.2x  Unspecified motorcycle rider injured in collision with pedal cycle in nontraffic accident

V21.3x  Person boarding or alighting a motorcycle injured in collision with pedal cycle

V21.4x  Motorcycle driver injured in collision with pedal cycle in traffic accident

V21.5x  Motorcycle passenger injured in collision with pedal cycle in traffic accident

V21.9x  Unspecified motorcycle rider injured in collision with pedal cycle in traffic accident

V22.xx  Motorcycle rider injured in collision with two- or three-wheeled motor vehicle

V23.xx  Motorcycle rider injured in collision with car, pick-up truck or van

V24.xx  Motorcycle rider injured in collision with heavy transport vehicle or bus

V25.xx  Motorcycle rider injured in collision with railway train or railway vehicle

V26.xx  Motorcycle rider injured in collision with other nonmotor vehicle

V27.xx  Motorcycle rider injured in collision with fixed or stationary object

V28.xx  Motorcycle rider injured in noncollision transport accident

V29.xx  Motorcycle rider injured in other and unspecified transport accidents

(See 4th and 5th character requirements for codes V20.0-V29. 7th character also required.)

Chapter 21  Factors Influencing Health Status and Contact with Health Services

Z59.82  Transportation insecurity

Z59.86  Financial insecurity

Z59.87  Material hardship

Z71.87  Encounter for pediatric-to-adult transition counseling

Z79.6  Long term (current) use of immunomodulators and immunosuppressants
\[Z79.62x\] Long term (current) use of immunosuppressant
\[Z79.63x\] Long term (current) use of chemotherapeutic agent
\[Z79.64\] Long term (current) use of myelosuppressive agent
\[Z79.69\] Long term (current) use of other immunomodulators and immunosuppressants
\[Z79.85\] Long-term (current) use of injectable non-insulin antidiabetic drugs

***************************************************
**Disclaimer*****************************************************

The Tennessee Chapter of the American Academy of Pediatrics (TNAAP) is not affiliated with any other organization, vendor, or company. The information contained herein is intended for educational purposes only, and any other use (including, without limitation, reprint, transmission or dissemination in whole or in part) is strictly prohibited. Although reasonable attempts have been made to provide accurate and complete information, neither the publisher nor any person associated with TNAAP warrant or guarantee the information contained herein is correct or applicable for any particular situation. TNAAP will not undertake to update any information provided herein. In all cases, the practitioner or provider is responsible for use of this educational material, and any information provided should not be a substitution for the professional judgment of the practitioner or provider.

Resources: *ICD-10-CM 2023*